DEBN z Email Formats

Medical Equipment Manufacturing • Renens, Vaud, Switzerland • 1-10 Employees

DEBN z Email Formats

DEBN z uses 2 email formats. The most common is {first name}{last name} (e.g., johndoe@debn.eu), used 66.7% of the time.

Format	Example	Percentage
{first name}{last name}	johndoe@debn.eu	66.7%
{first initial}{last name}	jdoe@debn.eu	33.3%

Key Contact at DEBN z

Michał Krużycki

Director of Operations ( board member)

Company overview

Headquarters	Chemin du Closel 5, 3rd floor, Renens, Vaud 1020, CH
Phone number	+41000688809
Website	debn.eu
Keywords	Medical Device, R&D, Commercialization, Prostate Cancer, Clinical Trials, Urology, Medical Device Commercialization, Drug Coating, Prostate Biopsy
Founded	2017
Employees	1-10
Socials

About DEBN z

DEBN (Drug-Eluting Biopsy Needle) is a medical company developing a novel prostate biopsy needle for urologists which will reduce infectious complication rate. -- Overview -- Prostate cancer is the most common malignancy diagnosed among men in developed countries. The prostate biopsy is a gold standard for detecting this cancer. During this procedure, urologists use a disposable biopsy needle to collect samples of tissue for further analysis. Due to the invasive method of diagnosis patients are advised for oral antibiotics prophylaxis before a biopsy. -- Problem -- The standard biopsy procedure is related with the transfer of intestinal bacterial flora to the blood and prostate. In the recent years, infectious complication rate following prostate biopsies continues to increase. The reason for this phenomenon is the increasing bacterial resistance to the standard oral antimicrobial prophylaxis. Patients undergoing prostate biopsy are exposed to urinary tract infections, prostatitis, and even severe septic complications. Annual treatment cost of prostate biopsy-related complications and insurance payouts is estimated at 1.7 bn USD in the USA and Europe. -- Solution -- Prostate biopsy needle that delivers the optimal antibiotic combination directly to the prostate, precisely at the place where potential infections start. This application method allows to use a more effective antibiotic which is not allowed for oral prophylaxis.